Tempest Therapeutics (TPST) Misses Q3 EPS by 79c

Tempest Therapeutics (NASDAQ: TPST) reported Q3 EPS of ($0.79), $0.79 worse than the analyst estimate of $0.00.

For earnings history and earnings-related data on Tempest Therapeutics (TPST) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Marvel Biosciences extends private placement to Quebec investors